130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
Condition: HIV Infections
Interventions: Biological: HIV CTL MEP administered with RC529-SE adjuvant;   Drug: GM-CSF
3 Completed Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
Condition: HIV Infections
Interventions: Biological: EP-1233;   Biological: MVA-mBN32
4 Completed ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1;   Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo;   Biological: MN rgp120/HIV-1  placebo
5 Completed A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
6 Completed Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: IL-15 DNA adjuvant;   Biological: IL-12 DNA adjuvant
7 Completed Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: EP HIV-1090
8 Completed Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
9 Completed Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
10 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
11 Active, not recruiting Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
12 Active, not recruiting Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
Condition: HIV Infections
Intervention: Biological: Ad5.ENVA.48 HIV-1 vaccine
13 Completed A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults
Condition: HIV Infections
Intervention: Biological: HIV LFn-p24
14 Completed Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
Conditions: HIV Infections;   Pregnancy;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
15 Completed A Study to Test the Safety of Three Experimental HIV Vaccines
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: HIV p24/MF59 Vaccine;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
16 Completed A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.
Condition: HIV Infections
Interventions: Biological: HIV-1 Peptide Vaccine, Microparticulate Monovalent;   Biological: HIV-1 Peptide Immunogen, Multivalent
17 Completed Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
Condition: HIV Infections
Interventions: Biological: DNA Vaccine;   Biological: Placebo;   Biological: rMVA vaccine
18 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1 SF-2;   Biological: Env 2-3;   Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
19 Withdrawn Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
Conditions: HIV Infections;   Pregnancy;   HIV Seronegativity
Interventions: Biological: MF59;   Biological: rgp120/HIV-1 SF-2
20 Not yet recruiting Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
Condition: HIV Infections
Intervention: Biological: Experimental

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years